Announced Tue, 11 Aug · 18:03 IST
Board approves Q1 results, book closure for AGM on Sep 11, new auditor
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-5.7%1-day move
₹39.25
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-5.7-3.3-4.4-3.2-3.2-3.2-3.1-5.8——
Up moveDown movePending
AI summary
Sandu Pharma board approved Q1 FY27 results with revenue of Rs 16.39 cr (vs Rs 16.70 cr YoY) and PAT of Rs 2.83 lakh (vs Rs 2.33 lakh). Books closed Sep 4 to 11 for the 41st AGM on Sep 11 via video conferencing. Record date Sep 4 for FY26 dividend. New auditor M/s Dave & Dave appointed for 5 years. Material RPTs with Sandu Brothers Pvt Ltd tabled for member approval.
Likely market impact
Routine AGM-related announcements. Q1 PAT improved despite slight revenue dip. New auditor and related party deals need shareholder approval.